Learning,
Quality control,
Exosome,
MD,
Partnership,
Cell,
CDMO,
TIL,
Biotechnology,
Patient,
Gene,
Society,
Health,
TCR,
Annual general meeting,
NK,
CGMP,
Pharmaceutical industry THE WOODLANDS, Texas, and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies, today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.
Key Points:
- THE WOODLANDS, Texas, and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies, today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.
- The ADVA X3® is an advanced, fully automated platform for manufacturing cell therapies, streamlining processes and reducing costs.
- Additionally, the ADVA X3® system supports cell therapies such as NK, TCR, TIL and exosomes from activation to final cell product.
- "The collaboration with Cellipont Bioservices is a pivotal moment for us," said Dr. Ohad Karnieli, CEO of Adva Biotechnology.
Learning,
Quality control,
Exosome,
MD,
Partnership,
Cell,
CDMO,
TIL,
Biotechnology,
Patient,
Gene,
Society,
Health,
TCR,
Annual general meeting,
NK,
CGMP,
Pharmaceutical industry THE WOODLANDS, Texas and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies, today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.
Key Points:
- THE WOODLANDS, Texas and HAIFA, Israel, May 7, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Adva Biotechnology, an Israel-based private biotechnology company providing a decentralized, automated, and efficient manufacturing platform for advanced cell therapies, today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.
- The ADVA X3® is an advanced, fully automated platform for manufacturing cell therapies, streamlining processes and reducing costs.
- Additionally, the ADVA X3® system supports cell therapies such as NK, TCR, TIL and exosomes from activation to final cell product.
- "The collaboration with Cellipont Bioservices is a pivotal moment for us," said Dr. Ohad Karnieli, CEO of Adva Biotechnology.
CDMO,
AML,
Partnership,
Patient,
Acute myeloid leukemia,
Cancer,
Technology transfer,
MBA,
CCO,
Bone marrow,
NK,
Pharmaceutical industry Under the agreement, Cellipont Bioservices will be providing the technology transfer and production of Wugen's allogeneic CAR-T cell therapies at their new purpose-built 76,000 sq.
Key Points:
- Under the agreement, Cellipont Bioservices will be providing the technology transfer and production of Wugen's allogeneic CAR-T cell therapies at their new purpose-built 76,000 sq.
- Wugen is developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer.
- "We are excited to collaborate with Cellipont Bioservices, leveraging their expertise in cell therapy manufacturing to carry out our mission of bringing innovative CAR-T cell therapies to patients in need.
- "We are thrilled to partner with Wugen, Inc. in advancing their groundbreaking CAR-T cell therapies.
Catalent,
CDMO,
Growth,
AstraZeneca,
Patient,
UNC,
Business development,
Acquisition,
Tuskegee University,
Lentivirus,
Consultant,
Molecular biology,
Marketing,
UNC Kenan–Flagler Business School THE WOODLANDS, Texas, March 12, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Edwin Beale as its new Chief Commercial Officer, effective immediately.
Key Points:
- THE WOODLANDS, Texas, March 12, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Edwin Beale as its new Chief Commercial Officer, effective immediately.
- Edwin's leadership will be instrumental in further establishing Cellipont as a leading partner for CDMO services in the rapidly growing cell therapy market.
- In his new role, Mr. Beale will oversee all commercial operations at Cellipont, playing a pivotal role in driving strategic growth and expansion.
- I look forward to serving our clients and surpassing their expectations," said Edwin Beale, Chief Business Officer.
THE WOODLANDS, Texas, March 7, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), proudly announces the grand opening of its purpose-built 76,000 sq.
Key Points:
- THE WOODLANDS, Texas, March 7, 2024 /PRNewswire/ -- Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), proudly announces the grand opening of its purpose-built 76,000 sq.
- This facility includes 7 clean rooms, QC labs, temperature-controlled storage, segregated shipping bays, warehouse, and administrative offices, marking a significant milestone in Cellipont's mission to advance cell therapy development and manufacturing, while serving patients worldwide.
- ...marking a significant milestone in Cellipont's mission to advance cell therapy development and manufacturing, while serving patients worldwide.
- "Cellipont's commitment to advancing cell therapy manufacturing is truly commendable," commented Ann Tanabe, CEO of BioHouston.
Retrieved on:
Wednesday, October 11, 2023
Partnership,
Cryopreservation,
Society for Cryobiology,
Organization,
Society,
CGMP,
CDMO,
Patient,
Fine chemical,
Management,
Pharmaceutical industry,
Cryobiology Teaming up with Evia Bio brings a non-DMSO solution and a Cryopreservation Center of Excellence (CryoX) to Houston, TX.
Key Points:
- Teaming up with Evia Bio brings a non-DMSO solution and a Cryopreservation Center of Excellence (CryoX) to Houston, TX.
- CryoX's mission is to gather cryopreservation practitioners, thought leaders, technologies, and organizations with a shared goal of improving therapeutic "cold chain" excellence.
- Cellipont Bioservices has dedicated world-class meeting and training space, process development labs, equipment, and scientists to support CryoX's mission.
- "We are excited to host this critical initiative," said Darren Head, Executive Chairman of the Board of Cellipont Bioservices.
Retrieved on:
Tuesday, October 10, 2023
Neoplasm,
Research,
GBM,
Glioblastoma,
B cell,
Safety,
FDA,
Process,
Fast Track,
CDMO,
Woodlands,
Patient,
Vaccine,
Medical imaging,
Immunotherapy With a first of its kind approach, Diakonos' DOC1021 activates a natural anti-viral immune response against a patient's tumor.
Key Points:
- With a first of its kind approach, Diakonos' DOC1021 activates a natural anti-viral immune response against a patient's tumor.
- Due to the promising results in both safety and efficacy in its phase 1 trial, Diakonos recently received Fast Track designation by the FDA.
- "We are deeply honored to have been chosen as Diakonos' partner in this critical endeavor," stated Darren Head, Chairman of the Board of Cellipont Bioservices.
- "We could not be happier to find that partner in Cellipont, and we look forward to changing patient outcomes in GBM as well as other cancer indications."
Finance,
Clinical Trials,
Health Technology,
Professional Services,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
General Health,
Ology Bioservices,
GMP,
Business development,
Partnership,
Senior,
OrbiMed,
General partnership,
IPSC,
CDMO,
MSC,
Patient,
Investment,
CFO,
Growth,
Pharmaceutical industry,
Management Cellipont Bioservices (Cellipont), a cell therapy contract development and manufacturing organization (CDMO), announced a strategic debt facility investment from OrbiMed , a healthcare investment firm.
Key Points:
- Cellipont Bioservices (Cellipont), a cell therapy contract development and manufacturing organization (CDMO), announced a strategic debt facility investment from OrbiMed , a healthcare investment firm.
- The investment will be used by Cellipont to fully finance the previously announced state-of-the-art commercial facility for cell therapies and gene-modified cell therapies in The Woodlands, Texas.
- "We are energized by this partnership with OrbiMed, which helps us to bring this world-class facility to completion in 2023," said Deborah Wild, President and CEO of Cellipont.
- Matthew Rizzo, General Partner of OrbiMed, commented “OrbiMed is excited to partner with Cellipont for their continued growth.
